<?xml version='1.0' encoding='utf-8'?>
<document id="21386026"><sentence text="Evaluation of contraindicated drug-drug interaction alerts in a hospital setting." /><sentence text="Risks associated with contraindicated drug-drug interaction alerts (CDDIAs) should always outweigh benefits" /><sentence text=" Misclassified CDDIAs should be eliminated" /><sentence text="" /><sentence text="To review CDDIAs and determine if they are contraindicated according to Food and Drug Administration-approved product labeling and if there are circumstances in which contraindicated interactions are acceptable" /><sentence text="" /><sentence text="A cross-sectional observational and quality improvement study was conducted over two 1-year periods" /><sentence text=" The 20 most common CDDIAs from May 2007 to May 2008 and all CDDIAs from April 2008 to April 2009 were collected at a large teaching hospital" /><sentence text=" Horizon Meds Manager used First DataBank as the knowledge base for decision support" /><sentence text=" Interactions were deemed truly contraindicated if listed in the contraindications section of the labeling of at least one of the interacting drugs" /><sentence text=" Alerts were grouped by drug and pharmacologic class to evaluate the evidence supporting the relevance of these interactions" /><sentence text=" An expert panel determined when an alert was misclassified" /><sentence text=" A medical advisory committee determined whether a contraindicated drug-drug combination was acceptable" /><sentence text="" /><sentence text="Twelve (60%) of the most common 20 contraindicated interaction pairs from 2007 to 2008 were inappropriately classified" /><sentence text=" Half of the alerts were not truly contraindicated" /><sentence text=" The 8 truly contraindicated drug-drug pairs were ketorolac and other nonsteroidal antiinflammatory drugs or oral solid potassium products and anticholinergics"><entity charOffset="50-59" id="DDI-PubMed.21386026.s17.e0" text="ketorolac" /><entity charOffset="120-129" id="DDI-PubMed.21386026.s17.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.21386026.s17.e0" e2="DDI-PubMed.21386026.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21386026.s17.e0" e2="DDI-PubMed.21386026.s17.e1" /></sentence><sentence text=" Half of these interactions were subsequently deemed acceptable under specific circumstances" /><sentence text=" Similar results were found in the second year, with only 55" /><sentence text="1% of all CDDIAs being truly contraindicated despite eliminating some of the alerts that were misclassified in the first year" /><sentence text=" Nearly three fourths of legitimate CDDIAs were deemed acceptable under specific circumstances" /><sentence text="" /><sentence text="Most contraindicated drug-drug interaction alerts from a commercial knowledge base were inappropriately categorized and could be downgraded" /><sentence text=" Some contraindicated drug combinations are permissible under specific circumstances" /><sentence text=" Alerts suggesting that certain drugs should never be used together, but their use together is sometimes acceptable, contribute to alert fatigue" /><sentence text="" /></document>